ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Rifaximin

Also written as “Rifaximin 200 mg Tablet”, “Low Dose Rifaximin ER” and “High Dose Rifaximin ER”.

Its studies are mostly in Diarrhea · Hepatic Encephalopathy · Rosacea · Anemia, Sickle Cell · Crohn Disease, led by 4 companies.

Drug pageRifaximin: every studyAll 150 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 16, 201322 company-led studies, 1 open or runningNext primary completion: Apr 20, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bausch Health Companiesits history only161 open or runningphase 4since Apr 16, 2013Dec 22, 2005Apr 20, 2027phase 4 · NCT07285785
Alfasigma40 open or runningphase 2since Feb 19, 2015Feb 19, 2015none ahead
Novartisits history only10 open or runningphase 3since Sep 29, 2016Sep 29, 2016none ahead
Teva Pharmaceutical Industriesits history only10 open or runningphase 3since Jul 9, 2015Jul 9, 2015none ahead

Also a collaborator on its studies: bioRASI, Cromsource and Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Alfasigma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 19, 2015First study: phase 2 study in Vaginosis, BacterialFirst studyNCT02376972 · 392 enrolled · United States
  2. May 15, 2018Phase 2 study in Crohn DiseaseNCT03537157 · 43 enrolled · Italy
  3. Mar 5, 2019Phase 2 study in RosaceaNCT03864978 · 236 enrolled · Italy
  4. Oct 25, 2021Phase 2 study in RosaceaNCT05150587 · 216 enrolled · United States

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Bacterial DNA-directed RNA polymerase inhibitor”ChEMBL 37, by rule

Studies

All 4 Alfasigma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05150587Rosacea · United States2CompletedOct 20, 2022216
NCT03864978Rosacea · Italy2UNKNOWNApr 2020236
NCT03537157Crohn Disease · Italy2TerminatedJul 15, 202043
NCT02376972Vaginosis, Bacterial · United States2TerminatedFeb 2016392

How it is read

Names in the registry

  • “Rifaximin”, 12 entries
  • “Rifaximin 200 mg Tablet”, 1 entry
  • “Low Dose Rifaximin ER”, 1 entry
  • “High Dose Rifaximin ER”, 1 entry
  • “Rifaximin delayed release tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.